Preventing Postpartum Venous Thromboembolism With Low-Molecular-Weight Heparin: The PP-HEP Pilot Randomised Controlled Trial.

ABSTRACT:

Objective

Uncertainty surrounds the risk-benefit of low-molecular-weight heparin to prevent postpartum venous thromboembolism (VTE). Data from randomised clinical trials (RCT) are critically needed, but recent feasibility studies in North America yielded low participation rates, with <1 enrolment per month per centre. Our aim was to assess the feasibility of a trial of postpartum short-term enoxaparin in Europe.

Design

Pragmatic, open-label pilot randomised controlled trial (RCT).

Setting

Swiss tertiary hospital.

Population

Postpartum women, within 48 h of delivery, deemed at intermediate risk of VTE with at least one major risk factor (morbid obesity, thrombophilia, emergency caesarean section, pre-eclampsia, preterm delivery, intrauterine growth restriction o

SUBMITTER: Blondon M 

PROVIDER: S-EPMC11612613 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature